In endometrial cancer cells, liraglutide induces an upregulation in progesterone receptor (PGR) mRNA levels, promotes its protein expression, markedly enhances phosphorylated AMPK levels, and downregulates its downstream effector molecule p-P71S6K, ultimately inhibiting cell viability [58]. The gene discussed is PGR; the disease is endometrial cancer.